gdc

Immunotherapy

Recent Progress in Small-Cell Lung Cancer Therapy
Lung CancerImmunotherapy
Lung cancer is divided into 2 main categories that require different therapies. Most of the new therapies are for the common type, but recently, immunotherapy has shown promise for this less common lung cancer type.
Targeted Therapies and Immunotherapies Approved for Patients with Non–Small-Cell Lung Cancer in 2020-2022
Lung CancerImmunotherapyTargeted Therapies
This article highlights the new therapies targeting a specific biomarker that have become available for patients with non–small-cell lung cancer in the past 3 years, significantly improving patient survival.
Beyond Chemotherapy: Immunotherapy Offers a New Treatment Option for Women with Endometrial Cancer
ImmunotherapyEndometrial Cancer
Dr. Binder, of the University of California, San Diego, describes immunotherapy as the most recent advance in the treatment of endometrial cancer.
Immunotherapy Side Effects: Symptoms and Management
ImmunotherapySide-Effects Management
Many side effects of immunotherapy can be effectively managed with early detection and intervention. It is important that patients with cancer and their caregivers know what symptoms to look for.
Jemperli a New Immunotherapy Approved for All Patients with dMMR Solid Tumors
FDA Approvals, News & UpdatesImmunotherapy
On August 17, 2021, the FDA accelerated the approval of Jemperli (dostarlimab-gxly; from GlaxoSmithKline) injection, an immunotherapy and a PD-1 inhibitor, for the treatment of all adults with recurrent (coming back) or advanced mismatch repair-deficient (dMMR) solid tumors, including lung cancer, that progressed during or after systemic therapy and for whom there are no satisfactory alternative treatment options.
Immunotherapy Beneficial in Patients with Early-Stage Non–Small-Cell Lung Cancer and PD-L1 Expression
Lung CancerImmunotherapyBiomarkers
For the first time, the use of immunotherapy after surgical removal of the tumor and chemotherapy has shown benefits in patients with early-stage non–small-cell lung cancer (NSCLC) and PD-L1 expression, a biomarker found in some patients with NSCLC.
The Immunotherapy Surge
Issue IntroductionsImmunotherapy
In this special issue focused on immunotherapy, we take a deep dive into this exciting type of treatment, highlighting the role of genetic testing and new developments in lung, skin, and bladder cancer in improving patient outcomes.
Molecular Profiling and Immunotherapy Offered Me New Hope After Stage IV Lung Cancer Diagnosis
ImmunotherapyPatient StoriesLung CancerGenomic/Genetic Testing
Christie Bevington shares her story of how immunotherapy was the only treatment that helped stop her cancer progression and relieve her back pain caused by lung cancer.
Molecular Profiling Is Making Cancer Treatment Personal
ImmunotherapyMolecular TestingGenomic/Genetic Testing
Tim Dorius, MD, explains the role of molecular profiling in relation to immunotherapy, and how oncologists can now look at the genetic makeup of a tumor to identify specific mutations or other biomarkers.
Page 1 of 8
Results 1 - 10 of 72

Subscribe to CONQUER: the patient voice

Receive timely cancer news & updates, patient stories, and more.


Country
Race or Ethnicity
Gender
Profession or Role
Primary Interest
Other Interests